Wegovy is the first semaglutide product FDA-approved specifically for chronic weight management. At a higher dose than Ozempic, it delivers more significant weight loss results. A daily oral pill form has expanded access for injection-averse patients.
Book a Free Consultation
Both contain semaglutide, but Wegovy is FDA-approved specifically for weight management at a higher maximum dose (2.4mg vs 1.0mg for Ozempic). This means Wegovy may produce more significant weight loss results.
Yes. An oral daily pill version of semaglutide has been approved, expanding access for patients who prefer not to inject. Your Vitelize physician can discuss which form is right for you.
The SELECT trial demonstrated a 35% reduction in major adverse cardiovascular events in patients taking semaglutide, establishing significant heart health benefits beyond weight loss.
Coverage is expanding but varies significantly by plan. Wegovy’s FDA approval for weight management helps with coverage compared to off-label use of other medications. Your Vitelize team can help navigate options.
GLP-1 therapy is typically ongoing. Studies show weight regain is common after stopping. Vitelize’s resistance training program helps build metabolic resilience, but your physician will create a long-term plan tailored to your goals.
The SELECT trial actually showed cardiovascular benefits. However, your Vitelize physician will evaluate your complete medical history to determine if Wegovy is appropriate for your specific situation.
Wegovy carries a boxed warning for thyroid C-cell tumors. Contraindicated in patients with MTC history or MEN2. Risks include pancreatitis, gallbladder disease, hypoglycemia, kidney injury, serious allergic reactions, and suicidal ideation. Not recommended during pregnancy. Discuss all medical conditions with your physician.
Take the 2-minute eligibility quiz. Free, no obligation.
Am I Eligible?